RAF1 and renal cell carcinoma: As sorafenib has been shown to target the Raf/MEK/ERK pathway (Wilhelm et al, 2004; Liu et al, 2006), we proceeded to examine whether sorafenib-induced tumour growth suppression in RCC-derived xenografts was associated with inactivation of this signalling pathway.